Myelodysplastic Syndromes

• 

  Subject Areas on Research

  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. 
  • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). 
  • Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. 
  • Acute radiation injury: contingency planning for triage, supportive care, and transplantation. 
  • Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Apoptosis in haematological malignancies. 
  • Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. 
  • Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. 
  • Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. 
  • Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. 
  • Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Colony-stimulating factors: clinical applications. 
  • Commentary: targeting myelodysplastic syndromes. 
  • Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. 
  • Congenital bone marrow failure with myelodysplasia in siblings. 
  • Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. 
  • Cyclosporin A-related cerebral vasculopathy. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). 
  • Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. 
  • Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. 
  • Erdheim-Chester disease collides with myelodysplastic neoplasm in bone marrow. 
  • Estimation of economic costs associated with transfusion dependence in adults with MDS. 
  • Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. 
  • Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. 
  • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by "Occult" Myelodysplastic Neoplasm: Two Cases of Adult Patients With Evidence of Genomic Instability and Clonal Selection by Chemotherapy. 
  • Localization of technetium-99m-sestamibi in diffuse myelodysplastic processes. 
  • Long-term outcomes of myeloid growth factor treatment. 
  • Multiple distinct clones may co-exist in different lineages in myelodysplastic syndromes. 
  • Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myelodysplasia and deficiency of uridine diphosphate-galactose 4-epimerase. 
  • Myelodysplasia as masquerader: A woman with hypereosinophilic syndrome and twelve years of "chronic ITP". 
  • Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • Myelodysplastic syndromes clinical practice guidelines in oncology. 
  • Myelodysplastic syndromes in the United States: an update for clinicians. 
  • Myelodysplastic syndromes, version 2.2015. 
  • Myelodysplastic syndromes. 
  • Myelodysplastic syndromes: clinical practice guidelines in oncology. 
  • Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. 
  • Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. 
  • Myeloid growth factors. 
  • Myeloid neoplasms in the setting of chronic lymphocytic leukaemia/chronic lymphocytic leukaemia-like disease: a clinicopathological study of 66 cases comparing cases with prior history of treatment to those without. 
  • Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. 
  • Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. 
  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. 
  • NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. 
  • Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. 
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Palliative and End-of-Life Care in Myelodysplastic Syndromes. 
  • Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study. 
  • Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. 
  • Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. 
  • Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. 
  • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 
  • Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. 
  • Recent progress in the treatment of myelodysplastic syndrome in adult patients. 
  • Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. 
  • Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells. 
  • TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. 
  • Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome. 
  • Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. 
  • Telomerase activity in normal leukocytes and in hematologic malignancies. 
  • The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. 
  • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. 
  • Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. 
  • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). 
  • Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots. 
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. 
  • Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 
  • Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. 
  • Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • Xist RNA is a potent suppressor of hematologic cancer in mice. 
  • t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor of Pediatrics, in the School of Medicine, Immunology
  • Erba, Harry Paul, Instructor in the Department of Medicine, Duke Cancer Institute
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Troy, Jesse David, Assistant Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics